Australia markets closed

Corcept Therapeutics Incorporated (0I3Q.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
31.54+0.56 (+1.81%)
At close: 07:08PM BST

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270

Full-time employees352

Key executives

NameTitlePayExercisedYear born
Dr. Joseph K. Belanoff M.D.Co-Founder, President, CEO & Director2.43MN/A1957
Mr. Atabak MokariCFO & Treasurer863.03kN/A1977
Mr. Sean MaduckPresident of Endocrinology1.05M2.7M1977
Dr. William Guyer Pharm.D.Chief Development Officer1.03M135k1968
Mr. Gary Charles RobbChief Business Officer & Secretary1.08M3.01M1963
Mr. Joseph Douglas LyonChief Accounting & Technology OfficerN/AN/A1978
Dr. Hazel Hunt Ph.D.Chief Scientific Officer895.16k1.75M1960
Ms. Amy FloodChief Human Resources & Communications OfficerN/AN/AN/A
Ms. Monica TelladoPresident of Emerging MarketsN/AN/A1973
Mr. Roberto W. VieiraPresident of OncologyN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corporate governance

Corcept Therapeutics Incorporated’s ISS governance QualityScore as of 1 July 2024 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.